What were the eligibility criteria for the “high-risk node-negative” group for NCIC-CTG MA.20, a phase III trial investigating WBI + RNI for high-risk node-negative or node-positive breast cancer treated with BCS and adjuvant chemotherapy and /or endocrine therapy?